These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 11681260

  • 21. [Advanced prostate cancer with normal serum prostate-specific antigen values].
    Komura T, Yamagiwa K, Ogura H, Kohjimoto Y, Ohkawa T, Inagaki T, Ebisuno S, Senzaki A.
    Hinyokika Kiyo; 1998 May; 44(5):303-6. PubMed ID: 9656099
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [The usefulness of prostate-specific antigen assay for the early detection and follow up of the prostate cancer].
    Saito Y.
    Nihon Rinsho; 1998 Aug; 56(8):1989-93. PubMed ID: 9750493
    [Abstract] [Full Text] [Related]

  • 25. [Prostate-specific antigen as a tumor marker of prostate carcinoma].
    Wymenga LF, Mensink HJ.
    Ned Tijdschr Geneeskd; 1999 Aug 21; 143(34):1733-8. PubMed ID: 10494319
    [Abstract] [Full Text] [Related]

  • 26. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
    Stamey TA, Johnstone IM, McNeal JE, Lu AY, Yemoto CM.
    J Urol; 2002 Jan 21; 167(1):103-11. PubMed ID: 11743285
    [Abstract] [Full Text] [Related]

  • 27. [Advancements in PSA-based screening for prostate cancer].
    Ito K.
    Rinsho Byori; 2004 Jul 21; 52(7):611-7. PubMed ID: 15344561
    [Abstract] [Full Text] [Related]

  • 28. [Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)].
    Tsuchiya N, Ohyama C, Habuchi T.
    Gan To Kagaku Ryoho; 2005 Feb 21; 32(2):275-80. PubMed ID: 15751649
    [Abstract] [Full Text] [Related]

  • 29. PSA doubling time as a predictive factor on repeat biopsy for detection of prostate cancer.
    Shimbo M, Tomioka S, Sasaki M, Shima T, Suzuki N, Murakami S, Nakatsu H, Shimazaki J.
    Jpn J Clin Oncol; 2009 Nov 21; 39(11):727-31. PubMed ID: 19674994
    [Abstract] [Full Text] [Related]

  • 30. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ, Kranse R, de Koning HJ, Schröder FH.
    Urology; 2004 Feb 21; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [Abstract] [Full Text] [Related]

  • 31. Hepatocyte growth factor and interleukin-6 in combination with prostate volume are possible prostate cancer tumor markers in patients with gray-zone PSA levels.
    Nishimura K, Arichi N, Tokugawa S, Yoshioka I, Namba Y, Kishikawa H, Takahara S, Ichikawa Y.
    Prostate Cancer Prostatic Dis; 2008 Feb 21; 11(3):258-63. PubMed ID: 17876341
    [Abstract] [Full Text] [Related]

  • 32. Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies.
    Rydén L, Egevad L, Ekman P, Hellström M.
    Scand J Urol Nephrol; 2007 Feb 21; 41(4):302-7. PubMed ID: 17763221
    [Abstract] [Full Text] [Related]

  • 33. [Prostate-specific antigen and its related parameters in detecting prostate cancer].
    Kuruma H, Egawa S.
    Gan To Kagaku Ryoho; 2003 Jan 21; 30(1):11-5. PubMed ID: 12557698
    [Abstract] [Full Text] [Related]

  • 34. Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer.
    Naya Y, Fritsche HA, Bhadkamkar VA, Mikolajczyk SD, Rittenhouse HG, Babaian RJ.
    Urology; 2004 Mar 21; 63(3):492-8. PubMed ID: 15028444
    [Abstract] [Full Text] [Related]

  • 35. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A, Dworschack RT, Partin AW.
    J Urol; 2002 Aug 21; 168(2):504-8. PubMed ID: 12131298
    [Abstract] [Full Text] [Related]

  • 36. Measurement of prostate specific antigen complexed to alpha1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4-20 ng/mL.
    Nakano Y, Okamura K, Takamura S, Okamoto N, Narishima M, Yoshino Y, Hattori R, Ono Y, Ohshima S, Nagasaka T.
    Int J Urol; 2005 Aug 21; 12(8):721-7. PubMed ID: 16174045
    [Abstract] [Full Text] [Related]

  • 37. Is transition zone biopsy valuable in benign prostatic hyperplasia patients with serum prostate-specific antigen >10 ng/ml and prior negative peripheral zone biopsy?
    Abdel-Khalek M, Sheir KZ, El-Baz M, Ibrahiem el-H.
    Scand J Urol Nephrol; 2005 Aug 21; 39(1):49-55. PubMed ID: 15764271
    [Abstract] [Full Text] [Related]

  • 38. Early detection of prostate cancer: is PSA a reliable option?
    Okihara K, Babaian RJ.
    Tex Med; 2001 Feb 21; 97(2):59-62. PubMed ID: 11233061
    [Abstract] [Full Text] [Related]

  • 39. Is there a role for serum human tissue kallikrein in detection of prostate cancer?
    Ochiai A, Shukla A, Davis JW, Fritsche HA, Bhadkamkar V, Babaian RJ.
    Urology; 2007 Sep 21; 70(3):519-22. PubMed ID: 17905108
    [Abstract] [Full Text] [Related]

  • 40. Proprostate-specific antigen: its usefulness in the era of multiple-core prostate biopsy.
    Miyakubo M, Ito K, Yamamoto T, Takechi H, Ohi M, Suzuki K.
    Int J Urol; 2009 Jun 21; 16(6):561-5. PubMed ID: 19456991
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.